The European medical technology landscape is undergoing a profound paradigm shift driven by the convergence of computational neuroscience, microelectronics, and advanced materials science. At the forefront of this transformation is neuromuscular electrical stimulation (NMES) and its closely related sibling, functional electrical stimulation (FES). Historically confined to clinical environments as analog, open-loop, and manually operated rehabilitation modalities, modern NMES

The European healthtech and medtech sectors have entered a phase of disciplined maturity, transitioning away from the venture subsidised experimentation of the early 2020s toward an era characterised by industrialisation and regulatory Darwinism. In the current market environment of 2025 and 2026, the criteria for a successful Series A funding round have shifted fundamentally. Investors no longer prioritise raw user acquisition or speculative growth; instead, they demand a ri